Does ticagrelor reduce ischaemic events and total mortality compared to clopidogrel in patients with NSTE-ACS, independent of revascularization?
Ticagrelor provides consistent benefits over clopidogrel in reducing ischemic events and mortality in NSTE-ACS patients, regardless of whether they undergo revascularization within the first 10 days.
In patients with NSTE-ACS, benefit of ticagrelor over clopidogrel in reducing ischaemic events and total mortality was consistent with the overall PLATO trial, independent of actually performed revascularization during the initial 10 days.
Lindholm et al. (Fri,) studied this question.